Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over nine indications across various species and non-prescription products targeting approximately seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Virend, Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm. Canalevia is its lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm Calf and Neonorm Foal are its lead non-prescription products to improve gut health and normalize stool formation.
Jaguar Animal Health, Inc.
News
(NetworkNewsWire) Jaguar Animal Health, Inc. (NASDAQ:JAGX), a company in the business of developing and commercializing gastrointestinal products for companion animals, horses, and production animals, recently had its company outlook updated by Aegis Capital Corp.
###
1,396 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 11) (Since Published: 1396)